Inhibitor Development in Hemophiliacs: The Roles of Genetic versus Environmental Factors

ABSTRACT

Approximately 5 to 7% of patients with hemophilia A have inhibitory antibodies to factor (F) VIII, which increases to ~13% in patients with severe disease. The strongest determinant of the risk of inhibitor development identified is the type of mutation in the FVIII gene that gives rise to the disease. However, accumulating evidence clearly indicates that other genetic factors (e.g., major histocompatibility complex alleles and other immune-modulatory genes) and factors associated with treatment (e.g., type of FVIII concentrate, route of administration, and age of first exposure) may also influence the risk of inhibitor development. There is much interest in identifying such genetic and treatment-related factors to help minimize the risk of inhibitor development and improve treatment outcomes.

KEYWORDS

Inhibitory antibodies to FVIII - inhibitor development - FVIII prophylaxis

REFERENCES

• 1 Ananyeva N, Khrenov A, Darr F et al.. Treating haemophilia A with recombinant blood factors: a comparison.  Expert Opin Pharmacother. 2004;  5 1061-1070
• 2 Wight J, Paisley S. The epidemiology of inhibitors in haemophilia A: a systematic review.  Haemophilia. 2003;  9 418-435
• 3 Paisley S, Wight J, Currie E, Knight C. The management of inhibitors in haemophilia A: introduction and systematic review of current practice.  Haemophilia. 2003;  9 405-417
• 4 Oldenburg J, Picard J K, Schwaab R et al.. HLA genotype of patients with severe haemophilia A due to intron 22 inversion with and without inhibitors of factor VIII.  Thromb Haemost. 1997;  77 238-242
• 5 Addiego J, Kasper C, Abildgaard C et al.. Increased frequency of inhibitors in African American hemophilia patients.  Blood. 1994;  84(suppl 1) 239 (abst 943)
• 6 Astermark J. Assessing genetic basis and non-genetic factors, and overall incidence rate of inhibitor development in PUPs: HIPS and HIGS update. Paper presented at: XVth Annual Hemophilia Research Study Update Meeting January 21-24, 2005 San Juan, Puerto Rico;
• 7 Scharrer I, Bray G L, Neutzling O. Incidence of inhibitors in haemophilia A patients-a review of recent studies of recombinant and plasma-derived factor VIII concentrates.  Haemophilia. 1999;  5 145-154
• 8 Gill J C. The role of genetics in inhibitor formation.  Thromb Haemost. 1999;  82 500-504
• 9 Astermark J, Berntorp E, White G C, Kroner B L. The Malmo International Brother Study (MIBS): further support for genetic predisposition to inhibitor development in hemophilia patients.  Haemophilia. 2001;  7 267-272
• 10 Hay C R, Ludlam C A, Colvin B T et al.. Factor VIII inhibitors in mild and moderate-severity haemophilia A. UK Haemophilia Centre Directors Organisation.  Thromb Haemost. 1998;  79 762-766
• 11 Berntorp E, Astermark J, Donfield S et al.. Genetic factors and inhibitor development: the Hemophilia Inhibitor Genetics Study, design and methods.  Haemophilia. 2004;  10(suppl 3) 53-66
• 12 White G C, DiMichele D, Mertens K et al.. Utilization of previously treated patients (PTPs), noninfected patients (NIPs), and previously untreated patients (PUPs) in the evaluation of new factor VIII and factor IX concentrates. Recommendation of the Scientific Subcommittee on Factor VIII and Factor IX of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis.  Thromb Haemost. 1999;  81 462
• 13 Giles A R, Rivard G E, Teitel J, Walker I. Surveillance for factor VIII inhibitor development in the Canadian hemophilia A population following the widespread introduction of recombinant factor VIII replacement therapy.  Transfus Sci. 1998;  19 139-148
• 14 Lorenzo J I, Lopez A, Altisent C, Aznar J A. Incidence of factor VIII inhibitors in severe haemophilia: the importance of patient age.  Br J Haematol. 2001;  113 600-603
• 15 van der Bom J G, Mauser-Bunschoten E P, Fisher K, van den Berg H M. Age at first treatment and immune tolerance to factor VII in severe hemophilia.  Thromb Haemost. 2003;  89 475-479
• 16 Santagostino E, Mancuso M E, Rocino A et al.. Environmental risk factors for inhibitor development in children with haemophilia A: a case-control study.  Br J Haematol. 2005;  130 422-427
• 17 Sharathkumar A, Lillicrap D, Blanchette V S et al.. Intensive exposure to factor VIII is a risk factor for inhibitor development in mild hemophilia A.  J Thromb Haemost. 2003;  1 1228-1236
• 18 von Auer C, Oldenburg J, Anuswald G et al.. The development of inhibition directed against factor VIII after continuous infusion of factor VIII concentrates in patients with hemophilia A.  J Thromb Haemost. 2003;  suppl abst P123
• 19 Yee T T, Lee C A. Oral immune tolerance induction to factor VIII via breast milk, a possibility?.  Haemophilia. 2000;  6 591
• 20 Knobe K E, Tengborn L I, Petrini P, Ljung R C. Breastfeeding does not influence the development of inhibitors in haemophilia.  Haemophilia. 2002;  8 657-659